Novel therapeutic approaches in the treatment of children with hepatoblastoma

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 9, 2002, Pages 751-755

  Katzenstein, Howard M ^a,d   Rigsby, Cynthia ^a   Shaw, Peter H ^b   Mitchell, Torrey L ^c   Haut, Paul R ^a   Kletzel, Morris ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Hepatoblastoma; High dose therapy; Irinotecan; Peripheral blood stem cells; Transplant

Indexed keywords

ALPHA FETOPROTEIN; AMIFOSTINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MELPHALAN; MESNA; VINCRISTINE;

ARTICLE; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; FOLLOW UP; HEPATOBLASTOMA; HIGH RISK PATIENT; HUMAN; INFECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SURGICAL APPROACH; THORAX PAIN; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 0036899624     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200212000-00014     Document Type: Article

References (28)

1. Bellani FF, Massimino M. Liver tumors in childhood: Epidemiology and clinics. J Surg Oncol 1993;119-21.
2. Evans AE, Land VJ, Newton WA, et al. Combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer 1982;50:821-6.
3. Exelby PR, Filler RM, Grosfeld JL. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey-1974. J Pediatr Surg 1975;10:329-37.
4. Ortega JA, Krailo MD, Haas JE. et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: A report from the Children's Cancer Study Group. J Clin Oncol 1991;9:2167-76.
5. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18:2665-75.
6. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach-results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18:3819-28.
7. Robertson PL, Muraszko KM, Axtell RA. Hepatoblastoma metastatic to brain: Prolonged survival after multiple surgical resections of a solitary brain lesion. J Pediatr Hematol Oncol 1997;19:168-71.
8. Black CT, Luck SR, Musemeche CA, et al. Aggressive excision of pulmonary metastases is warranted in the management of childhood hepatic tumors. J Pedatr Surg 1991;26:1082-6.
9. Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases. Cancer 2000;89:1845-53.
10. Feusner JH, Krailo MD, Haas JE, et al. Treatment of pulmonary metastases of initial stage 1 hepatoblastoma in childhood. Report from the Children's Cancer Group. Cancer 1993;71:859-64.
11. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: A report from the Children's Cancer Group. J Clin Oncol 1997;15:1190-7.
12. Matsumoto Y, Suzuki T, Ono H, et al. Response of alpha-fetoprotein to chemotherapy in patients with hepatomas. Cancer 1974;34:1602-6.
13. Rodriguez-Galindo C, Radomski K, Stewart CF, et al. Clinical use of topoisomerase 1 inhibitors in anticancer treatment. Med Pediatr Oncol 2000;35:385-402.
14. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase 11 study. J Pediatr Hematol Oncol 1998;20:315-8.
15. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 2001;7:32-7.
16. Cohn SL, Moss TJ, Hoover M, et al. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant 1997;20:543-51.
17. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
18. Ahmed T, Lake DE, Beer M, et al. Single and double autotransplants for relapsing/refractory Hodgkin's disease: Results of two consecutive trials. Bone Marrow Transplant 1997;19:449-54.
19. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: The experience of the European Bone Marrow Transplant Solid Tumor Registry. Med Pediatr Oncol 1994;22:11-4.
20. Hara J, Osugi Y, Ohta H, et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant 1998;22:7-12.
21. Yoshinari M, Imaizumi M, Hayashi Y, et al. Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: A therapeutic approach for incompletely resected tumor. Tohoku J Exp Med 1998;184:247-54.
22. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 1996;18:352-61.
23. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24.
24. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
25. Perry A, Mehta J, Iveson T, et al. Guillain-Barré syndrome after bone marrow transplantation. Bone Marrow Transplant 1994;14:165-7.
26. Eliashiv S, Brenner T, Abramsky O, et al. Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation. Bone Marrow Transplant 1991;8:315-7.
27. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10:795-803.
28. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54:1269-75.